Phathom Pharmaceuticals (PHAT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.09
- Surprise
- +100.0%
- Revenue (period 2026-06-30)
- $74.3M
- Score at report (before → after)
- 6.7 → 6.7/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Buy (Wait) (6.7/10) to Hold at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAT Sell at 6.7/10.
3 of the last 4 quarters beat the estimate; this quarter's +100.0% surprise compares with a +57.2% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Concentration risk — Product: VOQUEZNA
- Concentration risk — Counterparty: Takeda License
- Risk below floor (2.6 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.83
- Price target
- $17.80
- Stop
- $7.43
- Upside to target
- +127.3%
- Reward-to-risk
- 9.4:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
PHAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $660.2M
- P/E (fwd)
- 7.6
- 52-week range
- $8.07–$18.31
- Off 52-week high
- 57.2%
- RSI (14)
- 37
- Volume vs avg
- 1.86×
- Score today
- 6.7/10